Module 6 Neoplasia Flashcards

1
Q

Neoplasm

A
  • Tumour
  • Abnormal mass of tissue
  • Excessive cell division/evasion of apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cancer

A
  • Malignant
  • Deregulated growth
  • Ability to invade tissues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Benign Tumour Naming

A
  • Suffix oma
  • Named based on architectural pattern
  • Tissue type
  • Exceptions melanoma & lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Malignant Tumour Naming

A
  • Classified based on tissue type
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sarcoma Suffix

A
  • Connective tissue
  • Liposarcoma (fat cells)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Carcinoma Suffix

A
  • Epithelial cells
  • Adenocarcinoma (cell that forms glands)
  • Squamous cell carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Differentiation

A
  • Extent to which cells resemble normal
  • Well, moderately or poorly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anaplasia

A
  • Lack of differentiation
  • Do not resemble any tissue
  • High degree of atypia & pleomorphism (shape/size change)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Growth Rate

A
  • Benign slower than malignant
  • Correlates to blood supply
  • Tumour cells promote angiogenesis
  • Inverse correlation with differentiation
  • Poor differentiation grows faster
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Benign Characteristics

A
  • Well circumscribed
  • No invasion
  • Expansile growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Malignant Characteristics

A
  • Irregular/ill-defined margins
  • Invade & destroy tissue
  • Infiltrative growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Carcinoma Growth

A
  • Begin as localized growths originating from single cell
  • Confined to epithelium
  • Basement membrane in tact (high grade dysplasia/ situ)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Metastasis

A
  • Tumour discontinuous from primary lesion
  • Involves other tissue
  • Sign of malignancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lymphatic Spread

A
  • Most common in carcinomas
  • Spread to lymph nodes through lymphatic drainage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hematogenous Spread

A
  • Carcinomas & sarcomas
  • Lungs & liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Local Effects

A
  • Symptoms can occur with benign & malignant
  • Bleeding
  • Pain
  • Obstruction
  • Tumour can undergo infection, rupture, ulceration
17
Q

Hormonal Effects

A
  • Hormone producing tumours
  • B cell adenoma in pancreas (insulin production, hyperglycemia)
  • Adrenal cortex adenoma (steriod production)
18
Q

Cancer Cachexia

A
  • Progressive loss of fat & lean body mass
  • Reduced food intake (abnormalities in taste)
  • Reduced synthesis & storage of fat
  • Increased metabolism of fatty acids
  • Not due to nutritional demand of tumour
19
Q

Parameoplastic Syndrome

A
  • Symptoms not explained by tumour spread
  • Early signs of neoplasm, clinical problem indicator
  • Endocrine
  • Neurological
  • Blood cell abnormalities
20
Q

Cancer Grading

A
  • Pathological assessment
  • Estimates aggressiveness of neoplasm
  • Includes differentiation, mitoses, necrosis
  • 3 tier scale
21
Q

Cancer Staging

A
  • Clinical based on information obtained prior to treatment
  • Pathological based on information from treatment
  • Tumour size
  • Extent of spread to lymph nodes
  • Metastasis in other organs
22
Q

TNM Staging System

A
  • Tumour
  • Nodes
  • Metastases
23
Q

American Joint Committee on Cancer (AJCC)

A
  • Stages 0 to 4
  • Similar factors to TNM system
24
Q

Reasons to Stage Cancer

A
  • Common language across providers & patients
  • Treatment guide
  • Prognosis estimation
  • Comparison over time
  • Clinical trial standardization
25
Genetic Mutation Causes
- Radiation - Carcinogen exposure - Infection - Failure of cellular proof-reading mechanisms
26
Tumour Suppressors
- Inhibit proliferation - Control cell growth - Down regulate cell cycle - Repair DNA - Act as checkpoint for DNA damage - Mutations result in function loss
27
Proto-Oncogene
- Code normal proteins - Promote growth & survival of cell - Cause cellular proliferation - Inhibit cell death - Mutation/deregulation results in cancer
28
Cancer Progression
- Initiation - Promotion (premalignant cell proliferation) - Transformation (alteration produces malignant cells) - Progression (malignant cells divide)
29
Cancer Hallmarks
- Evading apoptosis - Self-sufficiency in growth signals - Insensitivity to anti-growth signals - Tissue invasion & metastasis - Limitless replicative potential - Sustained angiogenesis
30
Non-Modifiable Risk Factors
- Age - Sex - Ethnicity - Geography - Genetic susceptibility - Precursor lesions/preneoplastic conditions - Reproductive history
31
Modifiable Risk Factors
- Smoking - Obesity - Physical activity - Diet - Alcohol consumption - Injection drug use - Sexual history - UV radiation exposure
32
Carcinogens
- Cause genetic damage to cells - Chemical (cigarettes, asbestos) - Radiation (UV, ionizing) - Viral & microbial
33
Screening Purpose
- Identify asymptomatic individuals - With an elevated risk of cancer - Further diagnostic testing after early identification
34
Cervical Cancer Progression
- HPV infection (HPV Vaccine) - High grade dysplasia develops (HSIL) - Pap test intervention (prior to 10 years) - Invasive squamous cell carcinoma
35
Breast Cancer Development
- Carcinoma in situ (DCIS) precursor lesion - Mammography detection - Surgery to prevent progression - 3-9 years invasive breast
36
Colon Cancer Progression
- Colonic adenoma precursor lesion - Colonoscopy/FIT test detection - Remove - 10 years invasive cancer
37
Cancer Screening Principles
- Will be a major health problem - More treatable if detected early - Acceptable test for those eligible - Inexpensive - High sensitivity (subjects with cancer test positive) - High specificity (subjects without cancer test negative) - Screenings show reduced mortality